456 related articles for article (PubMed ID: 31662821)
1. Precision medicine in gastric cancer.
Bonelli P; Borrelli A; Tuccillo FM; Silvestro L; Palaia R; Buonaguro FM
World J Gastrointest Oncol; 2019 Oct; 11(10):804-829. PubMed ID: 31662821
[TBL] [Abstract][Full Text] [Related]
2. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
3. What's New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives.
Tirino G; Pompella L; Petrillo A; Laterza MM; Pappalardo A; Caterino M; Orditura M; Ciardiello F; Galizia G; De Vita F
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30205505
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives.
Pellino A; Riello E; Nappo F; Brignola S; Murgioni S; Djaballah SA; Lonardi S; Zagonel V; Rugge M; Loupakis F; Fassan M
World J Gastroenterol; 2019 Oct; 25(38):5773-5788. PubMed ID: 31636471
[TBL] [Abstract][Full Text] [Related]
5. Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safety.
Narita Y; Muro K
Expert Opin Drug Saf; 2017 Mar; 16(3):319-327. PubMed ID: 27976952
[TBL] [Abstract][Full Text] [Related]
6. Overview of Chemotherapy for Gastric Cancer.
Sato Y; Okamoto K; Kida Y; Mitsui Y; Kawano Y; Sogabe M; Miyamoto H; Takayama T
J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36835872
[TBL] [Abstract][Full Text] [Related]
7. Personalised Treatment in Gastric Cancer: Myth or Reality?
Tarazona N; Gambardella V; Huerta M; Roselló S; Cervantes A
Curr Oncol Rep; 2016 Jul; 18(7):41. PubMed ID: 27215435
[TBL] [Abstract][Full Text] [Related]
8. Molecular Characterization of Gastric Carcinoma: Therapeutic Implications for Biomarkers and Targets.
Kankeu Fonkoua L; Yee NS
Biomedicines; 2018 Mar; 6(1):. PubMed ID: 29522457
[TBL] [Abstract][Full Text] [Related]
9. Comparison and applicability of molecular classifications for gastric cancer.
Serra O; Galán M; Ginesta MM; Calvo M; Sala N; Salazar R
Cancer Treat Rev; 2019 Jul; 77():29-34. PubMed ID: 31195213
[TBL] [Abstract][Full Text] [Related]
10. Gastric Carcinoma at the Era of Targeted Therapies.
Dreanic J; Dhooge M; Sion E; Brezault C; Chaussade S; Coriat R
Curr Drug Targets; 2016; 17(15):1818-1826. PubMed ID: 25944013
[TBL] [Abstract][Full Text] [Related]
11. Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.
Ali SM; Sanford EM; Klempner SJ; Rubinson DA; Wang K; Palma NA; Chmielecki J; Yelensky R; Palmer GA; Morosini D; Lipson D; Catenacci DV; Braiteh F; Erlich R; Stephens PJ; Ross JS; Ou SH; Miller VA
Oncologist; 2015 May; 20(5):499-507. PubMed ID: 25882375
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy in advanced gastric carcinoma: the future is beginning.
Schinzari G; Cassano A; Orlandi A; Basso M; Barone C
Curr Med Chem; 2014; 21(8):1026-38. PubMed ID: 24304282
[TBL] [Abstract][Full Text] [Related]
13. Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application.
Li K; Li J
Gastroenterol Res Pract; 2016; 2016():4105615. PubMed ID: 26880889
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity in Gastric Cancer: From Pure Morphology to Molecular Classifications.
Gullo I; Carneiro F; Oliveira C; Almeida GM
Pathobiology; 2018; 85(1-2):50-63. PubMed ID: 28618420
[TBL] [Abstract][Full Text] [Related]
15. The safety and efficacy of ramucirumab in combination with paclitaxel for the treatment of advanced gastric or gastro-esophageal junction adenocarcinoma.
Garrido M
Expert Rev Anticancer Ther; 2016 Oct; 16(10):1005-10. PubMed ID: 27582051
[TBL] [Abstract][Full Text] [Related]
16. Predictive biomarkers for targeted and cytotoxic agents in gastric cancer for personalized medicine.
Wang S; Yuan L
Biosci Trends; 2016 Jul; 10(3):171-80. PubMed ID: 27251446
[TBL] [Abstract][Full Text] [Related]
17. Metastatic gastric cancer - focus on targeted therapies.
Meza-Junco J; Sawyer MB
Biologics; 2012; 6():137-46. PubMed ID: 22807624
[TBL] [Abstract][Full Text] [Related]
18. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.
Díaz-Serrano A; Angulo B; Dominguez C; Pazo-Cid R; Salud A; Jiménez-Fonseca P; Leon A; Galan MC; Alsina M; Rivera F; Plaza JC; Paz-Ares L; Lopez-Rios F; Gómez-Martín C
Oncologist; 2018 Sep; 23(9):1092-1102. PubMed ID: 29700210
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints.
Alsina M; Moehler M; Hierro C; Guardeño R; Tabernero J
Target Oncol; 2016 Aug; 11(4):469-77. PubMed ID: 26880697
[TBL] [Abstract][Full Text] [Related]
20. Lapatinib.
Voigtlaender M; Schneider-Merck T; Trepel M
Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
